News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
712,707 Results
Type
Article (42221)
Company Profile (436)
Press Release (670050)
Multimedia
Podcasts (75)
Webinars (13)
Section
Business (208695)
Career Advice (2021)
Deals (36001)
Drug Delivery (103)
Drug Development (83555)
Employer Resources (173)
FDA (16414)
Job Trends (15089)
News (352707)
Policy (33060)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (5)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2641)
Accelerated approval (6)
Adcomms (24)
Allergies (83)
Alliances (50910)
ALS (91)
Alzheimer's disease (1417)
Antibody-drug conjugate (ADC) (126)
Approvals (16403)
Artificial intelligence (251)
Autoimmune disease (22)
Automation (14)
Bankruptcy (371)
Best Places to Work (11841)
BIOSECURE Act (18)
Biosimilars (103)
Biotechnology (330)
Bladder cancer (65)
Brain cancer (26)
Breast cancer (264)
Cancer (2110)
Cardiovascular disease (175)
Career advice (1687)
Career pathing (29)
CAR-T (149)
Cell therapy (422)
Cervical cancer (19)
Clinical research (67597)
Collaboration (822)
Compensation (496)
Complete response letters (24)
COVID-19 (2641)
CRISPR (42)
C-suite (233)
Cystic fibrosis (104)
Data (2061)
Decentralized trials (2)
Denatured (27)
Depression (47)
Diabetes (259)
Diagnostics (6405)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (123)
Drug pricing (104)
Drug shortages (26)
Duchenne muscular dystrophy (95)
Earnings (87507)
Editorial (37)
Employer branding (21)
Employer resources (147)
Events (115355)
Executive appointments (686)
FDA (17586)
Featured Employer (54)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (740)
Gene editing (107)
Generative AI (20)
Gene therapy (309)
GLP-1 (728)
Government (4484)
Grass and pollen (4)
Guidances (50)
Healthcare (19142)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (118)
Indications (27)
Infectious disease (2781)
Inflammatory bowel disease (139)
Inflation Reduction Act (11)
Influenza (51)
Intellectual property (91)
Interviews (311)
IPO (16772)
IRA (43)
Job creations (3699)
Job search strategy (1434)
Kidney cancer (9)
Labor market (35)
Layoffs (487)
Leadership (17)
Legal (7980)
Liver cancer (73)
Lung cancer (305)
Lymphoma (138)
Machine learning (4)
Management (58)
Manufacturing (284)
MASH (65)
Medical device (13483)
Medtech (13488)
Mergers & acquisitions (19720)
Metabolic disorders (682)
Multiple sclerosis (74)
NASH (19)
Neurodegenerative disease (96)
Neuropsychiatric disorders (30)
Neuroscience (1953)
NextGen: Class of 2025 (6755)
Non-profit (4546)
Northern California (2527)
Now hiring (37)
Obesity (369)
Opinion (221)
Ovarian cancer (75)
Pain (83)
Pancreatic cancer (80)
Parkinson's disease (149)
Partnered (20)
Patents (216)
Patient recruitment (100)
Peanut (47)
People (58545)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21238)
Phase II (29825)
Phase III (22062)
Pipeline (1113)
Policy (129)
Postmarket research (2601)
Preclinical (9060)
Press Release (67)
Prostate cancer (99)
Psychedelics (37)
Radiopharmaceuticals (261)
Rare diseases (390)
Real estate (6013)
Recruiting (66)
Regulatory (22644)
Reports (46)
Research institute (2415)
Resumes & cover letters (351)
Rett syndrome (4)
RNA editing (4)
RSV (39)
Schizophrenia (73)
Series A (133)
Series B (85)
Service/supplier (11)
Sickle cell disease (56)
Southern California (2195)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (29)
Startups (3758)
State (2)
Stomach cancer (14)
Supply chain (63)
Tariffs (16)
The Weekly (46)
United States (22258)
Vaccines (681)
Venture capitalists (38)
Weight loss (246)
Women's health (36)
Worklife (16)
Date
Last 7 days (473)
Last 30 days (2333)
Last 365 days (33981)
2025 (8990)
2024 (36301)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (736)
Alabama (56)
Alaska (7)
Arizona (235)
Arkansas (14)
Asia (39145)
Australia (6521)
California (5811)
Canada (1923)
China (492)
Colorado (256)
Connecticut (272)
Delaware (135)
Europe (85505)
Florida (850)
Georgia (198)
Idaho (57)
Illinois (523)
India (24)
Indiana (300)
Iowa (10)
Japan (149)
Kansas (105)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (867)
Massachusetts (4443)
Michigan (215)
Minnesota (382)
Mississippi (2)
Missouri (79)
Montana (29)
Nebraska (25)
Nevada (57)
New Hampshire (66)
New Jersey (1659)
New Mexico (30)
New York (1646)
North Carolina (997)
North Dakota (7)
Northern California (2527)
Ohio (197)
Oklahoma (14)
Oregon (37)
Pennsylvania (1297)
Puerto Rico (10)
Rhode Island (30)
South America (1109)
South Carolina (18)
South Dakota (1)
Southern California (2195)
Tennessee (96)
Texas (864)
Utah (172)
Virginia (140)
Washington D.C. (61)
Washington State (546)
West Virginia (3)
Wisconsin (51)
712,707 Results for "nikang therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NiKang Therapeutics® Completes Dosing of the First Cohort in a Phase 1 Study of NKT3964, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2 Degrader
March 10, 2025
·
3 min read
Drug Development
NiKang Therapeutics Doses First Patient in a Phase 1/1b Study of NKT3447, an Oral, Selective Inhibitor of CDK2 Which Reduces Cyclin E Expression
NiKang Therapeutics Inc. (“NiKang”) is a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs.
April 15, 2024
·
3 min read
Press Releases
NiKang Therapeutics® Announces First Patient Dosed in a Phase 1b/2 Study of NKT2152 in Combination with Standard-of-Care in First-Line Regimen for Hepatocellular Carcinoma
January 21, 2025
·
3 min read
Business
NiKang Therapeutics Appoints Joanne Lager, M.D., as Chief Medical Officer
NiKang Therapeutics Inc. today announced the appointment of Joanne (Jo) Lager, M.D., as Chief Medical Officer (CMO), reporting to Zhenhai Gao, Ph.D., Co-founder, President and Chief Executive Officer (CEO) of NiKang.
January 4, 2024
·
2 min read
BioCapital
NiKang Therapeutics Presents the Discovery and Unique Mechanism of Action of a Selective CDK2 Inhibitor NKT3447 at AACR Annual Meeting 2024
NiKang Therapeutics Inc. announced today the unveiling of NKT3447 at the American Association for Cancer Research (AACR) Annual Meeting 2024. NKT3447 is an orally bioavailable small molecule CDK2 inhibitor that exhibits high selectivity against CDK1 and other CDK.
April 5, 2024
·
3 min read
News
NiKang Therapeutics® Presents Discovery of NKT3964, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2 PROTAC Degrader for Cancer Therapy, at the EORTC-NCI-AACR Symposium 2024
October 24, 2024
·
3 min read
Business
NiKang Therapeutics Enters into Clinical Trial Collaboration and Supply Agreement to Evaluate NKT2152 in Combination with Standard-of-Care in First-Line Advanced Hepatocellular Carcinoma
NiKang Therapeutics Inc. today announced that it has entered into a clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd. (“Roche”) to evaluate NKT2152, a small molecule that inhibits hypoxia inducible factor 2α (HIF2α), in combination with standard-of-care atezolizumab (Tecentriq®) and bevacizumab (Avastin®) in first-line treatment of unresectable/advanced hepatocellular carcinoma (HCC).
December 8, 2023
·
2 min read
Business
NiKang Therapeutics Appoints Anne E. Borgman, M.D., to Board of Directors
NiKang Therapeutics Inc. today announced that Dr. Anne Borgman has been appointed to the company’s Board of Directors.
January 18, 2023
·
2 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance
April 3, 2025
·
4 min read
1 of 71,271
Next
